OB33 / Boehringer Ingelheim, Oxford BioTherapeutics - LARVOL DELTA

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies (GlobeNewswire) - "Oxford BioTherapeutics...announced that Boehringer Ingelheim has selected a third drug candidate, which will now advance into IND-enabling studies under their ongoing collaboration. The target, OB33, was identified using OBT’s proprietary OGAP-Verify discovery platform. As a result of this milestone, OBT will receive a payment from Boehringer....Under the multi-year collaboration, OBT has identified targets using the OGAP-Verify platform, while Boehringer is responsible for the development and commercialization of resulting product candidates."

Financing • New molecule • Oncology